The distinctive nature of HER2-positive breast cancers

N Engl J Med. 2005 Oct 20;353(16):1652-4. doi: 10.1056/NEJMp058197.
No abstract available

Publication types

  • Comment

MeSH terms

  • Antibodies, Monoclonal / pharmacology
  • Antibodies, Monoclonal / therapeutic use*
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use*
  • Apoptosis / drug effects
  • Breast Neoplasms / drug therapy*
  • Breast Neoplasms / metabolism
  • Drug Resistance
  • Female
  • Gene Expression Regulation, Neoplastic / drug effects
  • Genes, erbB-2
  • Humans
  • Receptor, ErbB-2 / drug effects*
  • Receptor, ErbB-2 / metabolism
  • Trastuzumab

Substances

  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Humanized
  • Antineoplastic Agents
  • Receptor, ErbB-2
  • Trastuzumab